Valeo Financial Advisors’s Enanta Pharmaceuticals ENTA Stock Holding History

Valeo Financial Advisors’s Portfolio ENTA Stock Details ENTA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-431	Closed	-$22K	–	1745
2020 Q2	$22K	Hold	431	–	–	﹤0.01%	1021
2020 Q1	$22K	Sell	431 -75	-15%	-$4K	﹤0.01%	865
2019 Q4	$31K	Sell	506 -295	-37%	-$18.3K	﹤0.01%	802
2019 Q3	$48K	Hold	801	–	–	0.01%	612
2019 Q2	$68K	Sell	801 -28	-3%	-$2.52K	0.01%	521
2019 Q1	$79K	Buy	829 +549	+196%	+$49.2K	0.01%	457
2018 Q4	$20K	Hold	280	–	–	﹤0.01%	710
2018 Q3	$22K	Hold	280	–	–	﹤0.01%	750
2018 Q2	$24K	Hold	280	–	–	﹤0.01%	708
2018 Q1	$23K	Hold	280	–	–	﹤0.01%	674
2017 Q4	$16K	Hold	280	–	–	﹤0.01%	719
2017 Q3	$13K	Buy	+280	New	+$11.3K	﹤0.01%	637

Other funds holding ENTA

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

KAM

Krensavage Asset Management New York $256M AUM 69.63% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Valeo Financial Advisors's ENTA Position: Q3 2020 in Review

Valeo Financial Advisors sold out of Enanta Pharmaceuticals (ENTA) in Q3 2020, closing a stake of 431 shares — an estimated $22K sold.

Valeo Financial Advisors first reported a position in ENTA in Q3 2017 and held it in 12 quarters. The position peaked at $79K in Q1 2019. 172 funds tracked by Wall St. Rank hold ENTA as of Q3 2020.

Valeo Financial Advisors reported no remaining Enanta Pharmaceuticals position as of Q3 2020 after selling out during the quarter.
Valeo Financial Advisors sold 431 Enanta Pharmaceuticals shares in Q3 2020, an estimated $22K.
Valeo Financial Advisors first reported a position in Enanta Pharmaceuticals in Q3 2017 and held it in 12 quarters.
Valeo Financial Advisors's Enanta Pharmaceuticals position peaked at $79K in Q1 2019.
172 funds tracked by Wall St. Rank held Enanta Pharmaceuticals as of Q3 2020.

Based on Valeo Financial Advisors's 13F filing for Q3 2020, filed 28 Oct 2020.